This report studies the global western blotting market for the forecast period of 2016 to 2021. This market is expected to reach USD 730.7 Million by 2021 from USD 574.8 Million in 2016, growing at a CAGR of 4.9 %.
The global western blotting market is segmented on the basis of product, application, end user and region.
In the coming years, the western blotting market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to increasing government interest in biomedical & biotechnology industry in China, government initiatives supported by funding in Japan, growing funding for agriculture research in India, increasing diagnosis and related funding in Australia, and growing prevalence of herpes simplex virus (HSV) in southeast Asia.
North America is expected to account for the largest share of the global market. This can be attributed to the increasing prevalence of HIV and Lyme disease in the U.S., rise in research funding and increasing production of genetically modified crops in the U.S., U.S.-China collaborative program for biomedical research, and HIV vaccine initiative in Canada.
The global western blotting market, based on the application is segmented into biomedical & biochemical research, disease diagnostics, agriculture, disease diagnostics, biologics, and quality control, among others. The biomedical & biochemical research segment is expected to account for the largest share of the global market, by application in 2016. However, the disease diagnostics segment is projected to grow at the highest CAGR from 2016 to 2021.
Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.S.), Advansta, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Cell Signaling Technology, Inc. (U.S.) are some of the key players in the market worldwide.